Date: 2012-07-18
Type of information: Initiation of the trial
phase: 3
Announcement: initiation of the study
Company: GSK (UK)
Product: herpes zoster vaccine (HZ/su) containing Agenus' QS-21 Stimulon®1 adjuvant
Action mechanism:
Disease: prevention of shingles (herpes zoster) in immunocompromised patients
Therapeutic area: Infectious diseases
Country:
Trial
details: This study will include approximately 200 clinical sites and enroll more than 1,400 patients 18 years of age or older undergoing hematopoietic stem cell transplantation (HCT).
The immunocompromised study is part of a Phase 3 clinical program that began in August 2010 and was previously announced by GSK. This program includes a global, randomized, placebo-controlled Phase 3 clinical study with the HZ/su vaccine, which contains QS-21, for the prevention of shingles and post-herpetic neuralgia in over 30,000 adult patients. Patient enrollment for this study has completed.
Latest
news: Agenus has announced that GSK herpes zoster vaccine candidate (HZ/su), which contains Agenus\' QS-21 Stimulon®1 adjuvant as a component of GSK\'s adjuvant system, has commenced a global, randomized, placebo-controlled Phase 3 clinical trial for the prevention of shingles (herpes zoster) in immunocompromised patients.
